Abstract：Objective: To observe the evaluation significance of prethrombotic state molecules and cystatin C (Cys-C) level in patients with coronary heart disease (CHD) for prognosis after intervention operation. Methods: 72 CHD patients who were admitted to the hospital were enrolled. All underwent percutaneous coronary intervention (PCI). The prethrombotic state molecules [plasma D-dimer (DD), thrombotic precursor protein (TpP), fibrinogen (Fbg), serum von Willebrand factor (vWF)] and Cys-C levels before and at 3d after treatment were compared. They were divided into good prognosis group and poor prognosis group according to follow-up results. The prethrombotic state molecules and Cys-C before and at 3d after treatment were compared between the two groups. Results: The levels of plasma D-D, TpP, Fbg, serum vWF and Cys-C at 3d after PCI were significantly higher than those before treatment (P<0.05). The proportion of patients with diabetes, hyperlipidemia, hypertension and smoking history in poor prognosis group was significantly higher than that in good prognosis group (P<0.05). DD, TpP, Fbg, vWF and Cys-C in both groups at 3d after treatment were significantly higher than those before treatment (P<0.05). At 3d after treatment, D-D, TpP, Fbg, vWF and Cys-C in poor prognosis group were significantly higher than those in good prognosis group (P<0.05). D-D, TpP, Fbg, vWF and Cys-C were independent risk factors for prognosis of patients with CHD after PCI (P<0.05). Conclusion: The levels of prethrombotic state molecules and Cys-C in patients with coronary heart disease have an increasing trend, and the higher the degree of increase, the worse the prognosis of patients, which can be used for prognosis evaluation.
唐敏, 史殿魁. 冠心病患者血栓前状态分子胱抑素C水平对其介入术后预后的意义研究[J]. 河北医学, 2019, 25(12): 1986-1989.
TANG Min, et al. Significance of Prethrombotic State Molecules and Cystatin C Level in Patients with Coronary Heart Disease for Prognosis after Intervention Operation. HeBei Med, 2019, 25(12): 1986-1989.
[1] Doshi D,Ben-Yehuda O,Bonafede M,et al.Underutilization of coronary artery disease testing among patients hospitalized with new-onset heart failure[J].Journal of the American College of Cardiology,2016,68(5):450~458. [2] Roberts J K,Rao S V,Shaw L K,et al.Comparative efficacy of coronary revascularization procedures for multivessel coronary artery disease in patients with chronic kidney disease[J].American Journal of Cardiology,2017,119(9):1344~1351. [3] 陈洁,崔颖,穆士杰.血栓弹力图与T2DM合并冠心病患者血清铁蛋白的相关性分析[J].中国输血杂志,2016,29(9):929~931. [4] 刘佳,高洁,马晓娟,等.血栓前状态及血小板聚集率与冠心病危险因素的相关性分析[J].中西医结合心脑血管病杂志,2018,16(5):513~516. [5] 李霞,程曼丽,纪玉强,等.胱抑素C浓度与冠心病患者冠状动脉病变程度的关系[J].岭南心血管病杂志,2017,23(6):681~684. [6] Lobo M D,Sobotka P A,Pathak A.Interventional procedures and future drug therapy for hypertension[J].European Heart Journal,2016,38(15):1101. [7] Zontar D,Kuhelj D,Skrk D,et al.Patient peak skin doses from cardiac interventional procedures.[J].Radiation Protection Dosimetry,2016,139(1~3):262~265. [8] 钟涛,许伟,胡海亮,等.应用TEG监测冠心病患者的凝血状态及评价抗血小板聚集效果的临床研究[J].中国实验血液学杂志,2018,26(5):1484~1491. [9] 赵健斌,谭宁,刘勇,等.术前胱抑素C水平对冠脉介入术后急性肾损伤发生和远期不良预后的预测价值[J].实用医学杂志,2016,32(8):1254~1257.
2019, Vol. 25 
冀公网安备13080202000677号